Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study.
View / Open Files
Authors
Fatayer, Hiba
Bannon, Finian
Copson, Ellen
Cutress, Ramsey I
Dave, Rajiv V
Grayson, Margaret
Holcombe, Christopher
Irshad, Sheeba
Irwin, Gareth W
O'Brien, Ciara
Palmieri, Carlo
Shaaban, Abeer M
Sharma, Nisha
Singh, Jagdeep K
Whitehead, Ian
NeST Study Research Collaborative
Publication Date
2022-05-11Journal Title
Br J Surg
ISSN
0007-1323
Publisher
Oxford University Press (OUP)
Pages
znac131
Type
Article
This Version
VoR
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Fatayer, H., O'Connell, R. L., Bannon, F., Coles, C., Copson, E., Cutress, R. I., Dave, R. V., et al. (2022). Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study.. Br J Surg, znac131. https://doi.org/10.1093/bjs/znac131
Abstract
Neoadjuvant chemotherapy (NACT) is increasingly being used to treat early breast cancer, and offers several advantages, including reducing the extent of breast and axillary surgery, and providing an in vivo assessment of tumour sensitivity to treatment1–4. Clinical trials have identified tumour subgroups with high rates of pCR. A pCR can be achieved in 45–90 per cent of human epidermal growth factor receptor 2-positive (HER2+) tumours and triple-negative breast cancer (TNBC), but the rate in oestrogen receptor-positive (ER+)/HER2-negative (HER2–) breast cancer remains below 10 per cent3,5. Historically, increasing pCR rates following NACT have not translated into more breast-conserving surgery (BCS), but more recent data suggest that NACT can result in surgical downstaging6.
Keywords
NeST Study Research Collaborative
Identifiers
External DOI: https://doi.org/10.1093/bjs/znac131
This record's URL: https://www.repository.cam.ac.uk/handle/1810/338234
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.